Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Multicenter, Open-label, Dose-finding Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent or Refractory Solid Tumors.

NCT01962103 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT01962103
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01962103 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Multicenter, Open-label, Dose-finding Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent or Refractory Solid Tumors.
Lead sponsor
Celgene
Phase
Phase 1/2
Overall status
Completed
Start date
December 4, 2013
Completion date
November 6, 2018
Enrollment
107 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, clinical oncology, dermatofibrosarcoma, ewing's sarcoma, ewing's tumor, fibrosarcoma, histiocytoma, malignant melanoma, melanoma, neoplasia, neoplasm, neuroblastoma, oncology, medical, osteogenic sarcoma, osteosarcoma tumor, pediatrics, osteosarcoma, rhabdomyosarcoma, sarcoma, ewing's, sarcoma, osteogenic, sarcoma, soft tissue, sarcoma, spindle cell, sarcomas, epitheliod, tumors